Concretely: peptide mapping · oxidation · cagrilintide.
I am trying to choose between two options that are usually discussed as though only one exists.
I am not optimising for price, but I am not indifferent to it either.
Which axes does this decision turn on?
The relevant limitation is that a mass-neutral substitution has the same molecular weight as the correct residue and can co-elute under a routine gradient.
The workflow: reduce and alkylate any disulfides, digest with a specific protease — trypsin cleaving after lysine and arginine is the usual choice — separate the fragments by reverse-phase chromatography, and identify each by mass.
Missed cleavages are normal and expected; a map with a moderate number of them is a normal map, not a failed one.
D-amino-acid substitutions being mass-identical is the structural reason intact mass cannot detect them and mapping plus fragmentation can.
Non-reduced mapping is how you confirm disulfide pairings.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs to know whether a mass-neutral substitution is plausible for the sequence, since that is the case mapping is for.
Sequence coverage is the headline quality metric. Anything below about ninety-five per cent leaves regions unexamined, and the unexamined regions are where a problem could sit undetected.
Put another way, for a short peptide, trypsin may produce too few fragments to be useful. Chymotrypsin, Glu-C or a combination gives better coverage on sequences with few basic residues.
A missing expected fragment is as informative as an unexpected one.
The short version: enzymatic digestion, chromatographic separation of the fragments, mass identification of each, and a comparison against the theoretical map.
The result is compared against the theoretical digest of the claimed sequence. A fragment at an unexpected mass localises a problem to a few residues; a missing expected fragment does the same from the other direction.
Cost is the practical objection. Mapping costs several times a purity assay, which is why it belongs on a first lot from a new supplier rather than on every lot.
Non-reduced peptide mapping is the accepted approach to confirming disulfide connectivity.
Ask for the coverage figure with any map. Without it the result is not interpretable.
Start with what you are trying to detect, because mapping answers a specific question — where in the sequence — rather than a general one.
Disulfide scrambling gives an unchanged intact mass with different connectivity. Non-reduced mapping — digesting without reducing first — is how the correct pairings are confirmed.
The caveat is that a map confirms sequence and says nothing about content, sterility or endotoxin.
Mapping is for mass-neutral problems. That is when it earns its cost.
Concretely, post-translational and chemical modifications show up as a mass shift on a specific fragment, which is exactly the information intact mass throws away.
A D-amino-acid substitution has an identical molecular weight to its L counterpart. It is invisible to intact mass, usually invisible to a routine gradient, and detectable by mapping combined with tandem fragmentation or by chiral analysis.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Commission it on a first lot from a new supplier, not on every lot.
edited 17 Jun 2025 by tandem_gradient — clarified the distinction between purity and content
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.